

WIN (Stanozolol Micronized)
Brand: ProLab
Pharmaceutical Form: Injectable Suspension
Presentation: 100ml/mg concentrated vial of 10 ml

Composition:

Each ml of Win contains 50 mg of micronized stanozolol, a version of the non-aromatizable anabolic steroid derived from Dihydrotestosterone (DHT). Stanozolol is known for its ability to promote quality muscle development, characterized by lean gains and advanced muscle definition without water retention. The micronization of this compound improves its bioavailability and allows for more efficient administration, ensuring a more uniform release of the active ingredient in the body. Unlike other steroids, Win is characterized by its ability to offer potent anabolism without the risks associated with estrogen conversion, making it a preferred choice for athletes seeking strength, endurance, and muscle definition.

THERAPEUTIC INDICATIONS:

Win is indicated to improve physical performance and promote the increase of lean muscle mass in high-level athletes and bodybuilders. It is especially useful in cutting phases, where the goal is to reduce body fat without losing muscle. In addition, it is used to improve endurance and accelerate recovery after intense workouts, allowing athletes to maintain high performance during prolonged competitions or demanding routines. Stanozolol is known for its ability to increase vascularity and muscle hardness, making it ideal for those who want a defined, dry-looking physique.

The use of Win in sports is aimed at both intermediate and advanced users, due to its balanced anabolic-androgenic profile. It is also widely used to improve strength without drastically increasing body weight, making it an attractive option for sports where weight control is crucial. Additionally, thanks to its low water retention capacity, it is a recommended choice for users who are prone to experiencing estrogen-related adverse effects, such as gynecomastia, when using other anabolic steroids.

RECOMMENDED DOSAGE:

The dosage of Win varies based on the user's goals, their experience with anabolic steroid use, and their personal tolerance. For beginner users, a dosage of 50 mg administered every other day (EOD) for a 6- to 8-week cycle is recommended. This schedule offers progressive muscle gains without significant overload of the endocrine system, allowing the user to take advantage of the anabolic effects without risk of severe complications.

For intermediate users, the dosage can be increased to 50 mg daily, maintaining a 6- to 8-week cycle. This dosage significantly improves muscle definition and strength, and is especially useful in the pre-competition phases. Advanced users with extensive experience using steroids may opt for doses of 100 mg daily for a 6-week cycle, although extreme caution is advised regarding liver and cardiovascular health, as these higher doses may increase the risk of side effects.

Regardless of experience level, it is not recommended to prolong the use of WINTROL beyond 8 weeks due to its potential for hepatotoxicity. Furthermore, to maximize benefits and minimize risks, it is recommended to combine stanozolol with other non-hepatotoxic injectable compounds, such as testosterone in its various forms, to maintain proper hormonal balance and prevent adverse effects.

ADMINISTRATION MODE:

WINTROL should be administered by deep intramuscular injection, preferably in large muscle groups such as the gluteus or thigh, to ensure efficient absorption. Due to its micronized form, WINTROL is easily suspended in water, making it easy to administer and avoiding complications such as abscesses at the injection site. It is important to shake the vial well before each use to ensure a homogeneous distribution of stanozolol in the suspension.

Administration should be performed on alternate days (EOD) to maintain stable levels of the compound in the body, which maximizes anabolic effects while minimizing fluctuation in the steroid's plasma concentration. To optimize efficacy and reduce the risk of irritation at the injection site, it is advisable to rotate administration sites on a regular basis.

CONTRAINDICATIONS:

WINT is contraindicated in patients with hypersensitivity to stanozolol or any of the excipients present in the formulation. It should not be used in people with a history of severe liver disease, such as cirrhosis or hepatitis, due to its hepatotoxic potential.

